Retraction Note: MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma (Scientific Reports, (2016), 6, 1, (22793), 10.1038/srep22793);MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fan, Yue ^a   Xu, Li Li ^a   Shi, Chen Ye ^a   Wei, Wei ^b   Wang, Dan Song ^a   Cai, Ding Fang ^a  

^a FUDAN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; MICRORNA; MIRN454 MICRORNA, HUMAN; STROMAL CELL DERIVED FACTOR 1;

3' UNTRANSLATED REGION; ADULT; ANIMAL; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

3' UNTRANSLATED REGIONS; ADULT; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOKINE CXCL12; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84960984227     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-023-48852-5     Document Type: Erratum

References (55)

1. Han, H. & Von Hoff, D. D. SnapShot: pancreatic cancer. Cancer Cell 23, 424-424 e421, doi: 10.1016/j.ccr.2013.03.008 (2013).
2. di Magliano, M. P. & Logsdon, C. D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144, 1220-1229, doi: 10.1053/j.gastro.2013.01.071 (2013).
3. Song, W., Li, Q., Wang, L. & Wang, L. Modulation of FoxO1 Expression by miR-21 to Promote Growth of Pancreatic Ductal Adenocarcinoma. Cell Physiol Biochem 35, 184-190, doi: 10.1159/000369686 (2015).
4. Song, W., Li, Q., Wang, L., Huang, W. & Wang, L. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Sci rep 5, 10081, doi: 10.1038/srep10081 (2015).
5. Shi, W. et al. Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27. Tumour Biol 35, 11147-11151, doi: 10.1007/s13277-014-2423-x (2014).
6. Zhang, H. et al. TGFbeta signaling in pancreatic ductal adenocarcinoma. Tumour Biol 36, 1613-1618, doi: 10.1007/s13277-014-2757-4 (2015).
7. Mei, Q., Li, F., Quan, H., Liu, Y. & Xu, H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci 105, 755-762, doi: 10.1111/cas.12436 (2014).
8. Chen, B., Hou, Z., Li, C. & Tong, Y. MiRNA-494 inhibits metastasis of cervical cancer through Pttg1. Tumour Biol 36, 7143-9. doi: 10.1007/s13277-015-3440-0 (2015).
9. Jin, Y., Lu, J., Wen, J., Shen, Y. & Wen, X. Regulation of growth of human bladder cancer by miR-192. Tumour Biol 36, 3791-3797, doi: 10.1007/s13277-014-3020-8 (2015).
10. Liu, G., Jiang, C., Li, D., Wang, R. & Wang, W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol 35, 9801-9806, doi: 10.1007/s13277-014-2273-6 (2014).
11. Wang, F., Xiao, W., Sun, J., Han, D. & Zhu, Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol 35, 8653-8658, doi: 10.1007/s13277-014-2131-6 (2014).
12. Wang, Q., Cai, J., Wang, J., Xiong, C. & Zhao, J. MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol 35, 12743-12748, doi: 10.1007/s13277-014-2600-y (2014).
13. Zhang, J., Wang, S., Lu, L. & Wei, G. MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi's sarcoma. Tumour Biol 35, 12567-12573, doi: 10.1007/s13277-014-2577-6 (2014).
14. Sicard, F., Gayral, M., Lulka, H., Buscail, L. & Cordelier, P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther 21, 986-994, doi: 10.1038/mt.2013.35 (2013).
15. Tavano, F. et al. Changes in miR-143 and miR-21 expression and clinicopathological correlations in pancreatic cancers. Pancreas 41, 1280-1284, doi: 10.1097/MPA.0b013e31824c11f4 (2012).
16. Ali, S. et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70, 3606-3617, doi: 10.1158/0008-5472.CAN-09-4598 (2010).
17. Zhao, G. et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 12, 2569-2580, doi: 10.1158/1535-7163.MCT-13-0296 (2013).
18. Singh, S., Chitkara, D., Kumar, V., Behrman, S. W. & Mahato, R. I. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 334, 211-220, doi: 10.1016/j.canlet.2012.10.008 (2013).
19. Yu, S. et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 70, 6015-6025, doi: 10.1158/0008-5472.CAN-09-4531 (2010).
20. Osawa, T. & Shibuya, M. Targeting cancer cells resistant to hypoxia and nutrient starvation to improve anti-angiogeneic therapy. Cell Cycle 12, 2519-2520, doi: 10.4161/cc.25729 (2013).
21. Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11, 393-410, doi: 10.1038/nrc3064 (2011).
22. Li, Y. & Ye, D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets 10, 782-796 (2010).
23. Patiar, S. & Harris, A. L. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 13 Suppl 1, S61-75, doi: 10.1677/erc.1.01290 (2006).
24. Melillo, G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4, 601-605, doi: 10.1158/1541-7786.MCR-06-0235 (2006).
25. Shi, C. Y., Fan, Y., Liu, B. & Lou, W. H. HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression. Cell Physiol Biochem 32, 561-568, doi: 10.1159/000354460 (2013).
26. Teicher, B. A. & Fricker, S. P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16, 2927-2931, doi: 10.1158/1078-0432. CCR-09-2329 (2010).
27. Ratajczak, M. Z. et al. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20, 1915-1924, doi: 10.1038/sj.leu.2404357 (2006).
28. Cao, X., Han, Z. B., Zhao, H. & Liu, Q. Transplantation of mesenchymal stem cells recruits trophic macrophages to induce pancreatic beta cell regeneration in diabetic mice. Int J Biochem Cell Biol 53, 372-379, doi: 10.1016/j.biocel.2014.06.003 (2014).
29. Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10, 858-864, doi: 10.1038/nm1075 (2004).
30. Youn, S. W. et al. COMP-Ang1 stimulates HIF-1alpha-mediated SDF-1 overexpression and recovers ischemic injury through BMderived progenitor cell recruitment. Blood 117, 4376-4386, doi: 10.1182/blood-2010-07-295964 (2011).
31. Lerman, O. Z. et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. Blood 116, 3669-3676, doi: 10.1182/blood-2009-03-213629 (2010).
32. Ceradini, D. J. & Gurtner, G. C. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 15, 57-63, doi: 10.1016/j.tcm.2005.02.002 (2005).
33. Marquez-Curtis, L. A. & Janowska-Wieczorek, A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. BioMed research international 2013, 561098, doi: 10.1155/2013/561098 (2013).
34. Kucia, M. et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894, doi: 10.1634/stemcells.2004-0342 (2005).
35. Kucia, M. et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35, 233-245 (2004).
36. Salcedo, R. & Oppenheim, J. J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10, 359-370, doi: 10.1038/sj.mn.7800200 (2003).
37. Lieber, M., Mazzetta, J., Nelson-Rees, W., Kaplan, M. & Todaro, G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15, 741-747 (1975).
38. Davis, B. K. Isolation, culture, and functional evaluation of bone marrow-derived macrophages. Methods Mol Biol 1031, 27-35, doi: 10.1007/978-1-62703-481-4-3 (2013).
39. Weischenfeldt, J. & Porse, B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH protocols 2008, pdb prot5080, doi: 10.1101/pdb.prot5080 (2008).
40. Gordon, S. Alternative activation of macrophages. Nat Rev Immunol 3, 23-35, doi: 10.1038/nri978nri978 (2003).
41. Lamagna, C., Aurrand-Lions, M. & Imhof, B. A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80, 705-713, doi: jlb.1105656/jlb.1105656 (2006).
42. Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27, 451-483, doi: 10.1146/annurev.immunol.021908.132532 (2009).
43. Pollard, J. W. Trophic macrophages in development and disease. Nat Rev Immunol 9, 259-270, doi: 10.1038/nri2528 (2009).
44. Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661, doi: 327/5966/656/science.1178331 (2010).
45. Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604, doi: S1074-7613(10)00173-1/j.immuni.2010.05.007 (2010).
46. Xiao, X. et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci USA 111, E1211-1220, doi: 10.1073/pnas.1321347111 (2014).
47. Meng, F. et al. Interaction between pancreatic cancer cells and tumor-associated macrophages promotes the invasion of pancreatic cancer cells and the differentiation and migration of macrophages. IUBMB Life 66, 835-846, doi: 10.1002/iub.1336 (2014).
48. Hou, Y. C., Chao, Y. J., Tung, H. L., Wang, H. C. & Shan, Y. S. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer 120, 2766-2777, doi: 10.1002/cncr.28774 (2014).
49. Liu, C. Y. et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 93, 844-854, doi: 10.1038/labinvest.2013.69 (2013).
50. Kurahara, H. et al. Clinical significance of folate receptor beta-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol 19, 2264-2271, doi: 10.1245/s10434-012-2263-0 (2012).
51. Roy, I. et al. CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One 9, e90400, doi: 10.1371/journal.pone.0090400 (2014).
52. Liang, H. L. et al. MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac J Cancer Prev 16, 2397-2402 (2015).
53. Yu, L. et al. miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma. Oncotarget 6, 39225-39234, doi: 10.18632/oncotarget.4407 (2015).
54. Fang, B., Zhu, J., Wang, Y., Geng, F. & Li, G. MiR-454 inhibited cell proliferation of human glioblastoma cells by suppressing PDK1 expression. Biomed Pharmacother 75, 148-152, doi: 10.1016/j.biopha.2015.07.029 (2015).
55. Niu, G., Li, B., Sun, J. & Sun, L. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif 48, 348-355, doi: 10.1111/cpr.12187 (2015).